New immune cell engagers for cancer immunotherapy
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947 · cited 6×
“These artificially produced IgGA antibodies not only bind to human CD89 with similar affinity to IgA antibodies, but also bind to human CD64, CD32A, CD32B and C1q with similar affinity to IgG1 antibodies.”
InfluentialCytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 1×
“Broad T cell activation has been observed with CD28 superag-onists, but these molecules were found to be highly toxic in early clinical trials 39 .”
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835 · cited 1×
“Moreover, some of these cytotoxic mAbs have been engineered, through glyco-engineering (afucosylation) 93,94 or amino acid substitution 95 , to improve the binding of the Fc region to CD16A as a means of enhancing NK cell-mediated antitumour potential 96 .”
Topp, M. S., Gökbuget, N., Stein, A. S., Zugmaier, G., O'Brien, S., Bargou, R. C., Dombret, H., Fielding, A. K., Heffner, L., Larson, R. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71170-2 · Cited by 1,269
Harnessing innate immunity in cancer therapy
Demaria, O., Cornen, S., Daëron, M., Morel, Y., Medzhitov, R., & Vivier, E. (2019) · Nature · doi:10.1038/s41586-019-1593-5 · Cited by 957
Self-citationOverall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103485 · Cited by 924
Neutrophil cell surface receptors and their intracellular signal transduction pathways
Futosi, K., Fodor, S., & Mócsai, A. (2013) · International Immunopharmacology · doi:10.1016/j.intimp.2013.06.034 · Cited by 642
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521 · cited 1×
“Indeed, ADCP is a crucial, clinically relevant mode of action for the anti-CD38 mAb daratumumab 125 .”
IgG Fc engineering to modulate antibody effector functions
Wang, X., Mathieu, M., & Brezski, R. J. (2018) · Protein & Cell · doi:10.1007/s13238-017-0473-8 · Cited by 356
Cited by
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Current and emerging concepts for systemic treatment of metastatic colorectal cancer
Steup, C., Kennel, K. B., Neurath, M. F., Fichtner-Feigl, S., & Greten, F. R. (2025) · Gut · doi:10.1136/gutjnl-2025-335412 · Cited by 39
“These antibodies include bispecific T cell engagers (reviewed in 96–98 ) that provide a potential additional tool to direct immune cells into immune-cold tumours and could be combined with other forms of immunotherapies.”
Cancer-Associated Fibroblast Proteins as Potential Targets against Colorectal Cancers
Shah, R., Johnson, K. A., Lippert, A. E. L., Kraus, S. G., Emmerich, P. B., Pasch, C. A., Zhang, W., Matkowskyj, K. A., LeBeau, A. M., & Deming, D. A. (2024) · Cancers · doi:10.3390/cancers16183158 · Cited by 18
Metadata
- Authors
- Fenis, A., Demaria, O., Gauthier, L., Vivier, E., & Narni-Mancinelli, E.
- Venue
- Nature Reviews Immunology
- Published
- 2024-01-25
- Volume
- 24
- Issue
- 7
- Pages
- 471-486
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W4391231786
- Cited by
- 203
- References
- 15
- FWCI
- 16.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New immune cell engagers for cancer immunotherapy. https://app.cochat.ai/papers/10.1038/s41577-023-00982-7
- The paper
- Fenis, A., Demaria, O., Gauthier, L., Vivier, E., & Narni-Mancinelli, E. (2024). New immune cell engagers for cancer immunotherapy. Nature Reviews Immunology. https://doi.org/10.1038/s41577-023-00982-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.